We’ve recently updated our valuation analysis.

UroGen Pharma Valuation

Is URGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for URGN?

Other financial metrics that can be useful for relative valuation.

URGN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.1x
Enterprise Value/EBITDA-2.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does URGN's PS Ratio compare to its peers?

The above table shows the PS ratio for URGN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average5.5x
SELB Selecta Biosciences
2.2x-3.8%US$272.4m
YMAB Y-mAbs Therapeutics
4.5x21.5%US$193.9m
SLDB Solid Biosciences
13.3x-44.0%US$149.2m
SESN Sesen Bio
2.1x-65.9%US$127.9m
URGN UroGen Pharma
3.5x36.0%US$215.9m

Price-To-Sales vs Peers: URGN is good value based on its Price-To-Sales Ratio (3.5x) compared to the peer average (5.5x).


Price to Earnings Ratio vs Industry

How does URGN's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.1%
n/an/an/a

Price-To-Sales vs Industry: URGN is good value based on its Price-To-Sales Ratio (3.5x) compared to the US Biotechs industry average (12.9x)


Price to Sales Ratio vs Fair Ratio

What is URGN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

URGN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.5x
Fair PS Ratio7x

Price-To-Sales vs Fair Ratio: URGN is good value based on its Price-To-Sales Ratio (3.5x) compared to the estimated Fair Price-To-Sales Ratio (7x).


Share Price vs Fair Value

What is the Fair Price of URGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: URGN ($9.35) is trading below our estimate of fair value ($192.4)

Significantly Below Fair Value: URGN is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst URGN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$9.35
US$28.40
+203.7%
42.5%US$47.00US$11.00n/a5
Jan ’24US$8.87
US$28.40
+220.2%
42.5%US$47.00US$11.00n/a5
Dec ’23US$8.73
US$29.00
+232.2%
40.9%US$47.00US$11.00n/a5
Nov ’23US$11.72
US$32.60
+178.2%
41.4%US$51.00US$11.00n/a5
Oct ’23US$8.32
US$27.80
+234.1%
51.5%US$51.00US$10.00n/a5
Sep ’23US$7.67
US$27.80
+262.5%
51.5%US$51.00US$10.00n/a5
Aug ’23US$7.44
US$25.00
+236.0%
56.1%US$51.00US$10.00n/a5
Jul ’23US$8.18
US$25.00
+205.6%
56.1%US$51.00US$10.00n/a5
Jun ’23US$5.19
US$24.17
+365.6%
53.5%US$51.00US$10.00n/a6
May ’23US$7.06
US$24.33
+244.7%
52.4%US$51.00US$11.00n/a6
Apr ’23US$8.74
US$27.00
+208.9%
50.8%US$51.00US$11.00n/a5
Mar ’23US$5.94
US$34.00
+472.4%
41.6%US$51.00US$10.00n/a5
Feb ’23US$7.79
US$36.60
+369.8%
27.7%US$51.00US$23.00n/a5
Jan ’23US$9.51
US$39.80
+318.5%
28.3%US$51.00US$23.00US$8.875
Dec ’22US$11.92
US$39.80
+233.9%
28.3%US$51.00US$23.00US$8.735
Nov ’22US$17.02
US$42.60
+150.3%
27.4%US$55.00US$27.00US$11.725
Oct ’22US$17.09
US$42.60
+149.3%
27.4%US$55.00US$27.00US$8.325
Sep ’22US$18.11
US$42.60
+135.2%
27.4%US$55.00US$27.00US$7.675
Aug ’22US$15.50
US$39.33
+153.8%
26.5%US$51.00US$27.00US$7.446
Jul ’22US$15.66
US$39.17
+150.1%
27.1%US$51.00US$26.00US$8.186
Jun ’22US$18.86
US$36.57
+93.9%
32.0%US$51.00US$21.00US$5.197
May ’22US$19.45
US$37.43
+92.4%
29.5%US$51.00US$24.00US$7.067
Apr ’22US$19.63
US$38.43
+95.8%
32.2%US$57.00US$24.00US$8.747
Mar ’22US$20.46
US$41.00
+100.4%
31.8%US$59.00US$25.00US$5.947
Feb ’22US$21.87
US$41.00
+87.5%
31.8%US$59.00US$25.00US$7.797
Jan ’22US$18.02
US$43.00
+138.6%
29.3%US$59.00US$25.00US$9.517

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies